Myriad's PROLARIS Test Shown to Significantly Predict Prostate Cancer Outcome From Needle Biopsy Tissue

Myriad Genetics MYGN announced today that a presentation entitled "Prognostic value of a 46-gene cell cycle progression RNA signature for prostate cancer death in a conservatively managed watchful waiting needle biopsy cohort," was presented on Saturday, June 4, 2011 at the American Society of Clinical Oncology Annual Meeting in Chicago. The study demonstrates that the Company's 46-gene CCP molecular diagnostic test, PROLARIS, is the strongest predictor of cancer death for prostate cancer patients managed through watchful waiting. "These findings are of great potential clinical significance," stated Jerry Lanchbury Ph.D., Chief Scientific Officer of Myriad Genetics, Inc. "We believe that this latest study provides very strong evidence that the PROLARIS test has an important role to play in defining the aggressiveness of a given prostate cancer, at the point of biopsy, and therefore provides essential guidance to physicians and their patients on the appropriate course of treatment."